Join our daily newsletter At The Bell to receive exclusive market insights
- Kazia Therapeutics (KZA) enrols its first patient in the upcoming phase one clinical trial of EVT801
- EVT801 is a small molecule inhibitor of VEGFR3 and works by hindering lymphangiogenesis, the formation of new lymphatic vessels around the tumour
- The trial will be undertaken in two stages, with aims to determine the maximum tolerated dose and better understand the biochemical activity of the drug
- The study will be undertaken at the Institut Universitaire du Cancer de Toulouse Oncopole in France and will be led by Dr Carlos Gomez-Roca
- Shares in Kazia are up 1.27 per cent on the market and are trading at $1.59
Kazia Therapeutics (KZA) has enrolled its first patient in the upcoming phase one clinical trial of EVT801, an investigational cancer therapy.
EVT801 is a small molecule inhibitor of VEGFR3 and works by hindering lymphangiogenesis, the formation of new lymphatic vessels around the tumour.
The trial will be undertaken in two stages, with stage one to determine the maximum tolerated dose (MTD) and recommended phase two dose (RP2D) for EVT801.
Patients will first receive a low dose of EVT801, which will be progressively increased as the safety profile of the drug is determined.
The second stage will recruit 12 patients, six of which have been diagnosed with renal cell carcinoma (type of kidney cancer) and six with soft-tissue sarcoma (cancers that start in soft tissues such as muscle, blood vessels, tendons and nerves).
All 12 patients will receive EVT801 and RP2D, with aims to better understand the biochemical activity of the drug.
The study will be undertaken at the Institut Universitaire du Cancer de Toulouse Oncopole (IUCT-Oncopole) in Toulouse, France.
The lead investigator is Dr Carlos Gomez-Roca who is the medical oncologist and Chair of the Early Phase Unit at IUCT-Oncopole.
CEO Dr James Garner is excited to begin the trial.
“In the six months since we licensed EVT801, the Kazia and Evotec teams have been working assiduously to execute a first-in-human study of this very promising drug candidate,” Dr Garner commented.
“All of us in Kazia firmly believe that EVT801 has enormous potential as a novel cancer therapy and we look forward to working closely with the investigators to explore that potential.”
Shares in Kazia were up 1.27 per cent on the market and were trading at $1.59 at 1:20 pm AEDT.
